Abrogation of type I IFN signalling by using an antibody that blocks the IFNAR1 receptor negated the synergistic effects towards increasing survival of mice bearing intracranial CT-2A tumours following combined SMC and anti-PD-1 treatment (Fig. 7g). This evidence concerns the gene PDCD1 and neoplasm.